access-principles-1access-principles-2access-principles-3backcarrierdevelopmentease_of_administrationexportimplantableinjectablenon-implantablenon_carriernon_injectableother_featuresprintroute_of_administrationtherapeutic_areatype_of_tech
Back

Drug name

Last update: Oct 2026

VH4770359 (VH-359)

Developer(s)

ViiV Healthcare
export_notes

Drug information

Drug's link(s)

Not provided

Generic name

VH-359 (VH-4770359)

Brand names

investigational

Compound type

Small molecule

Drug class/category

capsid inhibitor

Lifecycle status

Not provided

Summary

Phase 1 started mid 2026

Approval status

investigational

Regulatory authorities

investigational

Therapeutic area(s)

  • HIV
Use case(s)

Not provided

Administration route

Oral

Associated long-acting platforms

Oral solid form

Use of drug

Ease of administration
  • Self-administered
  • To be determined
Frequency of administration
  • Weekly
  • Other/Variable/Unknown : To be determined
User acceptance
Not provided

Dosage

Available dose and strength

Not provided

Maximum dose

Not provided

Recommended dosing regimen

Not provided

Additional comments

Not provided

Dosage link(s)

Not provided

Related entries

Not provided

Additional information

Not provided

Developer(s)

ViiV Healthcare
Originator
United Kingdom

ViiV Healthcare

ViiV Healthcare is a pharmaceutical company that specializes in the development of therapies for HIV infection. The company is headquartered in Brentford in the United Kingdom and was initially formed in November 2009 as a part of a joint venture between GlaxoSmithKline and Pfizer. Shionogi joined in October 2012

Drug structure

Scale-up and manufacturing prospects

Scale-up prospects

Not provided

Tentative equipment list for manufacturing

Not provided

Manufacturing

Not provided

Specific analytical instrument required for characterization of formulation

Not provided

Excipients & delivery device(s)

Proprietary excipients used

Not provided

Novel excipients or existing excipients at a concentration above Inactive Ingredient Database (IID) for the specified route of administration

Not provided

Residual solvents used

Not provided

Delivery device(s)

No delivery device

Safety, Efficacy and Evidence Summary

Safety

Not provided

Efficacy

Not provided

Evidence Summary

Not provided

References and relevant studies

Not provided

There are either no relevant patents or these were not yet submitted to LAPaL

Please be informed that this site uses cookies. Learn more

Allow cookies